Work

A first-in-human, phase I, open-label study of a novel cancer vaccine labvax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps2700

Authors: Weijie Ma, Shuai Chen, Nancy L. Ogihara, Jasmine Huynh, Ariel Yen, Karen Kelly, Primo "Lucky" N. Lara, James A. Radosevich, Michael Babich, Tianhong Li

Institutions: UC Davis Comprehensive Cancer Center, University of California, Davis, University of California System

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Comprehensive Cancer Center, University of California, Davis

OpenAlex ID: W4286294447

Cites:

Cited by: 2

Related to: 10